InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Adalimumab Has Promise as Treatment for Early-Stage Dupuytren’s Disease
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has announced that adalimumab, its anti-TNF treatment, has shown potential to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease. According to the announcement, researchers at Oxford Population Health’s Health Economics Research Centre and the Kennedy Institute of Rheumatology have identified the potential; adalimumab is commonly used to treat conditions such as rheumatoid arthritis…